These results provide clues that not only the molecular mechanism of LY6K and ERα in breast cancer but also the inhibition of miR-192-5p in ERα-positive breast cancer and the overexpression of miR-500a-3p in ERα-negative breast cancer could be effective therapeutic agents. This evidence concerns the gene LY6K and breast cancer.